Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 18/20 | 0.79 |
| ▸ | CYP4A11 | Q02928 | 18/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070661 | 0.88 | CYP4F2 (1.00) | CYP4F2CYP4A11 | |
| SCHEMBL22098497 | 0.81 | CYP4F2 (0.71) | CYP4F2CYP4A11 | |
| SCHEMBL22070580 | 0.78 | CYP4F2 (0.55) | CYP4F2CYP4A11 | |
| SCHEMBL22070806 | 0.77 | CYP4F2 (0.79) | CYP4F2CYP4A11 | |
| SCHEMBL14539034 | 0.74 | RAB9A (0.62) | NPC1ALDH1A1RAB9A | |
| SCHEMBL12400239 | 0.69 | SLC7A5 (0.68) | CYP4F2CYP4A11NPC1ALDH1A1RAB9A | |
| SCHEMBL26690016 | 0.68 | SLC7A5 (0.59) | CYP4F2CYP4A11NPC1ALDH1A1RAB9A | |
| SCHEMBL2848161 | 0.68 | MAOB (0.60) | CYP4F2CYP4A11ALDH1A1RAB9ASLC7A5 | |
| SCHEMBL22070485 | 0.67 | CYP4F2 (0.80) | CYP4F2CYP4A11 | |
| SCHEMBL3944540 | 0.67 | P4HTM (0.57) | NPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885NPC1 2753/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885NPC1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.